Literature DB >> 20495634

Clinical factors predictive of malignant and premalignant cystic neoplasms of the pancreas: a single institution experience.

Natalie B Jones1, Ioannis Hatzaras, Nathaniel George, Peter Muscarella, E Christopher Ellison, W Scott Melvin, Mark Bloomston.   

Abstract

BACKGROUND: As cystic neoplasms of the pancreas are discovered with advanced imaging techniques, pancreatic surgeons often struggle with identifying who is at risk of having or developing pancreatic cancer. We sought to review our experience with the surgical management of cystic neoplasms of the pancreas to determine pre-operative clinical indicators of malignancy or premalignant (i.e. mucinous) lesions.
METHODS: Between 1996 and 2007, 114 consecutive patients with cystic neoplasms of the pancreas underwent a pancreatectomy. Invasive adenocarcinoma was identified in 35 whereas 79 had benign lesions. Mucinous lesions were considered premalignant and consisted of 29 intraductal papillary mucinous neoplasms (IPMN) and 17 mucinous cystic neoplasms (MCN). The remaining 33 benign lesions were serous microcystic adenomas. Descriptive statistics were calculated and multivariate logistic regression was performed. Receiver-operating characteristic (ROC) curves were constructed for continuous variables and the area under the curves compared. Likelihood ratios were calculated from the combinations of predictors.
RESULTS: Patients with pancreatic cancer arising from a cystic neoplasm were older than those with benign cysts. Mucinous lesions with or without associated cancer were more likely to be symptomatic and present with elevated serum carbohydrate antigen (CA)19-9 levels. Cancers more commonly presented in the head of the pancreas and were associated with longer hospitalizations after resection. Using multivariate logistic regression, size and elevated CA19-9 were predictors of malignancy whereas male gender and size were predictors of mucinous lesions with or without malignancy. Size, however, was not an accurate test to determine premalignant or malignant lesions using area under the ROC curve analysis whereas CA19-9 performed the best regardless of gender or lesion location.
CONCLUSIONS: Based upon our single institution experience with resection of cystic neoplasms of the pancreas, we advocate an aggressive surgical approach to any patient with a cystic neoplasm of the pancreas and associated elevated CA19-9.

Entities:  

Year:  2009        PMID: 20495634      PMCID: PMC2799619          DOI: 10.1111/j.1477-2574.2009.00114.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  30 in total

1.  Receiver operating characteristic curves and their use in radiology.

Authors:  Nancy A Obuchowski
Journal:  Radiology       Date:  2003-10       Impact factor: 11.105

Review 2.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

Review 3.  Cystic lesions of the pancreas. A diagnostic and management dilemma.

Authors:  G Garcea; S L Ong; A Rajesh; C P Neal; C A Pollard; D P Berry; A R Dennison
Journal:  Pancreatology       Date:  2008-05-23       Impact factor: 3.996

4.  Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Hiroki Ohge; Yasuo Hayashidani; Takeshi Sudo; Taijiro Sueda
Journal:  Surgery       Date:  2006-07-27       Impact factor: 3.982

5.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

Review 6.  A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients.

Authors:  Brian K P Goh; Yu-Meng Tan; Yaw-Fui A Chung; Pierce K H Chow; Peng-Chung Cheow; Wai-Keong Wong; London L P J Ooi
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

7.  Surgical treatment of incidentally identified pancreatic masses.

Authors:  Timothy L Fitzgerald; Andrew J Smith; Max Ryan; Mostafa Atri; Frances C Wright; Calvin H L Law; Sherif S Hanna
Journal:  Can J Surg       Date:  2003-12       Impact factor: 2.089

8.  Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas.

Authors:  M Sugiyama; Y Izumisato; N Abe; T Masaki; T Mori; Y Atomi
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

9.  Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study.

Authors:  William R Brugge; Kent Lewandrowski; Elizabeth Lee-Lewandrowski; Barbara A Centeno; Tara Szydlo; Susan Regan; Carlos Fernandez del Castillo; Andrew L Warshaw
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

10.  Exocrine pancreatic tumours and their histological classification. A study based on 167 autopsy and 97 surgical cases.

Authors:  T Morohoshi; G Held; G Klöppel
Journal:  Histopathology       Date:  1983-09       Impact factor: 5.087

View more
  10 in total

Review 1.  Diagnosis and management of pancreatic cystic neoplasms.

Authors:  Mathew James Keegan; Bharat Paranandi
Journal:  Frontline Gastroenterol       Date:  2019-03-01

2.  Predictors of early stages of histological progression of branch duct IPMN.

Authors:  Hiroshi Kurahara; Kosei Maemura; Yuko Mataki; Masahiko Sakoda; Satoshi Iino; Yuko Kijima; Sumiya Ishigami; Shinichi Ueno; Hiroyuki Shinchi; Shoji Natsugoe
Journal:  Langenbecks Arch Surg       Date:  2014-12-03       Impact factor: 3.445

3.  Differential Diagnosis of Pancreatic Epidermoid Cyst Without a Solid Component (Residual Splenic Tissue) vs. Mucinous Cystic Neoplasm.

Authors:  Kousei Ishigami; Akihiro Nishie; Hiroyuki Irie; Yoshiki Asayama; Yasuhiro Ushijima; Yukihisa Takayama; Daisule Okamoto; Nobuhiro Fujita; Takao Ohtsuka; Tetsuhide Ito; Naoki Mochidome; Hiroshi Honda
Journal:  J Gastrointest Cancer       Date:  2019-03

Review 4.  Pancreatic mucinous cystadenoma with serum CA 19-9 over 1,000,000 U/mL: a case report and review of the literature.

Authors:  Wilson L Costa; Henrique Mantoan; Rafael Horácio Brito; Héber S C Ribeiro; Alessandro L Diniz; André Luís Godoy; Igor Correia Farias; Maria Dirlei F S Begnami; Fernando Augusto Soares; Felipe J F Coimbra
Journal:  World J Surg Oncol       Date:  2015-02-25       Impact factor: 2.754

5.  Serum Carbohydrate Antigen 19-9 in Differential Diagnosis of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis.

Authors:  Shaobo Cao; Ya Hu; Xiang Gao; Quan Liao; Yupei Zhao
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

6.  CA19-9 for detecting recurrence of pancreatic cancer.

Authors:  Azadeh Azizian; Felix Rühlmann; Tanja Krause; Markus Bernhardt; Peter Jo; Alexander König; Mathias Kleiß; Andreas Leha; Michael Ghadimi; Jochen Gaedcke
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

7.  Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients.

Authors:  Fumiaki Watanabe; Koichi Suzuki; Sawako Tamaki; Iku Abe; Yuhei Endo; Yuji Takayama; Hideki Ishikawa; Nao Kakizawa; Masaaki Saito; Kazushige Futsuhara; Hiroshi Noda; Fumio Konishi; Toshiki Rikiyama
Journal:  Sci Rep       Date:  2021-10-21       Impact factor: 4.379

8.  Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors.

Authors:  Jacek A Smigielski; Lukasz Piskorz; Marcin Wawrzycki; Przemysław Dobielski; Małgorzata Pikala; Sławomir Jabłoński; Marian Brocki
Journal:  Arch Med Sci       Date:  2013-08-08       Impact factor: 3.318

Review 9.  Advanced endoscopic ultrasound management techniques for preneoplastic pancreatic cystic lesions.

Authors:  Hafiz Muhammad Sharjeel Arshad; Sheila Bharmal; Deniz Guney Duman; Suthat Liangpunsakul; Brian G Turner
Journal:  J Investig Med       Date:  2016-08-29       Impact factor: 2.895

10.  A new combined criterion to better predict malignant lesions in patients with pancreatic cystic neoplasms.

Authors:  Chungen Lan; Xin Li; Xiuchao Wang; Jihui Hao; He Ren
Journal:  Cancer Biol Med       Date:  2018-02       Impact factor: 4.248

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.